Mankind Pharma IPO: Issue Subscribed 14%, HNIs Subscribed One-Third Of quota On Day One

Mankind Pharma, a leading Indian pharmaceutical company, recently launched its Initial Public Offering (IPO). On the first day of initial public offering (IPO), the subscription rate was at 14%.

The response was mainly from non-institutional investors (NIIs), who subscribed to approximately 33%, followed by retail investors at 10% and qualified institutional investors (QIBs) at 8% of their allotted quota. As per BSE data, the company received bids for 40,57,417 shares, which is over 2,80,41,192 shares on offer.

Mankind Pharma share's GMP increased to Rs 92 per equity share, an increase of 8.5% over the top end of the share price range. The price range for its initial public offering was Rs 1,026-1,080 per equity share with a par value of Rs 1. The promoters and shareholders of the company aim to raise Rs 4,326.35 crore from the IPO at the top of the price range.

The offer is being made utilising the book-building approach, which requires that retail individual investors have access to at least 35% of the offer and non-institutional investors have access to at least 15% of the offer.Qualified institutional purchasers may only receive up to 50% of the bid.

Mankind Pharma is involved in the development, production, and marketing of a wide variety of pharmaceutical formulations for use in both acute and chronic therapeutic areas, in addition to a number of consumer healthcare items. The pharmaceutical company operates in a variety of acute and chronic therapeutic disciplines, such as respiratory, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, and vitamins/minerals/nutrients.